(@kerickson)

Goal 3: Advance Translational Research

Do Alpha-1 Antitrypsin Deficiency and Cystic Fibrosis Inform COPD? Have we been looking?

Cystic fibrosis (CF) and alpha-1 antitrypsin deficiency (AATD) share phenotypic features with common COPD including airflow obstruction and airway mucociliary dysfunction. Although research in CF and AATD has advanced our understanding of those rare diseases, it has yet to explain common COPD. Do Alpha-1 Antitrypsin Deficiency and Cystic Fibrosis Inform COPD? Could therapies currently in use or under development for ...more »

Voting

22 net votes
24 up votes
2 down votes
Active
(@nhlbiforumadministrator1)

Goal 2: Reduce Human Disease

Innovations in Red Cell Transfusion in Sickle Cell Disease

Challenges that need to be overcome in blood transfusion, especially in SCD, include: a. Adopting molecular genotyping as the standard in blood transfusion therapy. b. Advancing new generation, anti-oxidant hemoglobin-based oxygen carriers (HBOCs) for use in emergencies such as trauma, stroke, acute hemolysis, and in transfusion in SCD and related disorders. In SCD, HBOCs have the capacity to not only serve as substitutes ...more »

Voting

29 net votes
47 up votes
18 down votes
Active
(@nhlbiforumadministrator1)

Goal 3: Advance Translational Research

Paradigm shift in cardiac arrest rhythm and resuscitation

What resuscitation strategies targeted toward pulseless electrical activity (PEA)/asystole would be successful in preventing cardiac arrest (CA)? Furthermore, what are animal models of PEA/asystole, what is responsible of this major shift in the underlying rhythm of CA, and what is the phenotype?

Voting

-4 net votes
7 up votes
11 down votes
Active
(@rwise0)

Goal 3: Advance Translational Research

Novel Treatments for COPD

COPD is a major health problem leading to 140,000 deaths in the United States. Treatments are supportive, but there is a compelling need for treatments that modify the progression of the disease and that prevent exacerbations. There needs to be a research infrastructure that unites basic, translational, and clinical researchers to develop new approaches. Although this challenge had been met in the past with the now ...more »

Voting

16 net votes
23 up votes
7 down votes
Active
(@chenx106)

Goal 2: Reduce Human Disease

Impact of lung remodeling on congestive heart failure progression

End stage congestive heart failure (CHF) causes intensive lung remodeling beyond the type-2 pulmonary hypertension. CHF induced lung remodeling includes profound lung fibrosis, lung vascular remodeling and lung inflammation. Understanding CHF-induced lung remodeling is also critical to understand the right ventricular failure. However, this area is largely unstudied. Regulating CHF-induced lung remodeling and the underlying ...more »

Voting

13 net votes
15 up votes
2 down votes
Active
(@greg.martin)

Goal 2: Reduce Human Disease

Develop and validate a metric to address the full spectrum of patient-level comorbidities affecting critical illness

An individual metric to inform about the additive and not individual impact of comorbidities on critical illness and peri-operative mortality. For instance, we know the impact of COPD or MI or CKD on mortality after hemicolectomy, but not necessarily the additive impact of all three.

Voting

2 net votes
4 up votes
2 down votes
Active
(@jlaakso)

Goal 2: Reduce Human Disease

Hormonal influences on atherosclerotic cardiovascular disease (ASCVD)

Cardiovascular diseases are the leading cause of morbidity and mortality for both men and women worldwide. It has been established that post-menopausal women have decreased protection from ASCVD relative to premenopausal women and men. However, the hormonal basis of protection (or lack thereof) is not clear.

Voting

2 net votes
6 up votes
4 down votes
Active
(@jnoel0)

Goal 3: Advance Translational Research

NEW INFRASTRUCTURE FOR CLINICAL RESEARCH IN SLEEP AND CIRCADIAN DISORDERS

Much of the current clinical research on sleep and circadian research depends on cohorts designed for other purposes. While this has been helpful, such studies have limitations. These limitations are related to availability of in-depth phenotyping data and questions as to whether individuals identified in population studies are equivalent to those who present clinically with specific disorders. These concerns could ...more »

Voting

126 net votes
186 up votes
60 down votes
Active
(@nhlbiforumadministrator)

Goal 3: Advance Translational Research

Improving Community-Based Care for Sickle Cell Disease

Sickle cell treatment centers are located throughout the United States, primarily in urban areas, and play an invaluable role. However, there is a critical need to identify and educate primary care providers who can provide routine and preventive care, but will also know when to consult with/refer to hematologists and other appropriate providers when necessary.

Voting

9 net votes
9 up votes
0 down votes
Active